Infinity Pharmaceuticals and Roche have entered a master clinical supply agreement under which Roche will supply Gazyva (obinutuzumab) to Infinity for planned clinical studies to evaluate the combination of Gazyva and duvelisib (IPI-145), Infinity’s oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with hematologic malignancies. The companies have also entered into a material transfer agreement under which Infinity will supply Roche with duvelisib for use in Ro...